Mar 07, 2022 / 07:10PM GMT
Steve Mah - Cowen and Company, LLC - Analyst
All right. Good afternoon, everyone. I'm Steve Mah, the newest member of Cowen's tools and diagnostics research team joining Dan Brennan and Max Masucci. (Conference Instructions)
So it's our pleasure to welcome Emily Leproust and Jim Thorburn from Twist Bioscience to our conference. I think most people know Twist. So I think we'll forego the company introduction and just jump right into the fireside chat session. So today, we're going to focus on outlook for 2022, progress across the base business, pipeline development, and maybe some of your philosophy on some of your business decisions and how you see Twist evolving over the next three to five years.
Emily Leproust - Twist Bioscience Corporation - CEO & Co-Founder
Thanks for having us.
Questions and Answers:
Steve Mah - Cowen and Company, LLC - AnalystOkay. All right. So yeah, so first question, maybe we'll start from a high level first and then drill down later. But as I've known Twist for a long
Trustpilot
